Overall verdict
Sell
3.4/10
1-year performance
+27.17%
Score breakdown
Up 27.2% over 1 year, 62% of the 52-week range.
Strongest: Financial strength 8.7/10. Weakest: Shareholder return 0.0/10.
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.
Sector
Health Care
Industry
Biotechnology
Primary listing
Six
Switzerland
CEO
Mr. Orlando Oliveira
Founded
2004
Employees
94
Revenue / employee
824 626 CHF
Next earnings
September 30, 2026
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
18.84 CHF
52-week low
9.38 CHF
1-year performance
27.17%
Rising
Year-to-date performance
13.88%
Rising
Drawdown
-19.00%
Marked drawdown
Position in the 52-week range
62% of range
Gross margin 18.7%, the company loses 63.8% of its revenue, ROIC -62.8%, ROE -620.0%.
Net margin
-63.79%
Negative
Sector -229.34%|S&P 12.97%
Gross margin
18.74%
Low
Return on equity (ROE)
-620.02%
Negative
Sector -58.11%|S&P 16.52%
Return on invested capital (ROIC)
-62.82%
Negative
Free cash flow margin (FCF)
-45.11%
Negative
Margin stability
1147.9 pts
Very uneven
Revenue to net income
Growth
7.4/10Revenue up 112.7% over 1 year, 38.8% a year over 5.
Revenue (trailing 12 months)
77.2M CHF
Revenue growth (1y)
112.70%
Hyper-growth
Revenue growth (3y)
932.85%
Hyper-growth
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
-1438.89%
Sharply revised down
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 11.3x|S&P 23.0x
Forward P/E (adjusted)
89.8x
Very expensive
EV / EBITDA
—
N/A (loss)
Sector 13.4x|S&P 14.5x
PEG
—
Sector 1.05|S&P 0.86
P/E vs its own 5-year history
among the 1% highest valuations
At its historical high
Market cap
237M CHF
Financial strength
8.7/10Cash covers 23.0% of the debt, net debt/EBITDA -0.8x.
Net debt / EBITDA
-0.8x
Net cash
Gearing (net debt / equity)
—
Cash
22.4M CHF
Cash / market cap
9.48%
Solid
Cash / total debt
22.95%
Tight
Net debt
75.3M CHF
Equity
-11.8M CHF
Closed daily candles, 2 years
Last close on September 24, 2026: 15.02 CHF
- MM2015.67
- MM5015.54
- MM20015.28
- RSI 1441.3
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+3.10%
200-day average slope, 3 months
+9.21%
50-day average slope, 1 month
+0.42%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
2.95 % per day
Volatility change
-3.53%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | — | -1.21 (2) | 95 (2) | -22 (1) | — |
| 2027 | — | 0.17 (2) | 116 (2) | 8 (1) | — |
Amounts in millions of CHF, EPS in CHF per share. In brackets, the number of analysts. Consensus as of August 10, 2026.
Same sub-industry: 734 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | RCKT | 6.8 | N/A | 332M USD | Not meaningful (loss) | — | — | -4.5 % | 1.4x | -51.4 % | -14.6 % | ||
| 2 | CUV | 6.5 | 6.3 | 294M USD | 12.4x | 36.1 % | -1.0 % | 13.2 % | -6.0x | 8.3 % | -29.0 % | ||
| 3 | XFOR | 4.9 | 2.5 | 308M USD | Not meaningful (loss) | -568.8 % | 346.3 % | -57.6 % | 1.5x | — | -13.3 % | ||
| 4 | IKT | 4.4 | 0.9 | 300M USD | Not meaningful (loss) | — | — | -52.0 % | 2.4x | -14.2 % | 29.6 % | ||
| 5 | CATX | 4.4 | 1.6 | 299M USD | Not meaningful (loss) | -28516.1 % | -72.1 % | -39.2 % | 2.1x | -40.6 % | -21.4 % | ||
| 6 | ALERS | 3.6 | 4.1 | 287M USD | 51.9x | 2.9 % | 9.1 % | 2.6 % | -0.1x | 1.9 % | -1.4 % | ||
| 7 | SANN | 3.4 | 2.8 | 286M USD | Not meaningful (loss) | -63.8 % | 112.7 % | -62.8 % | -0.8x | -14.7 % | 27.2 % | ||
| 8 | AMRN | 3.3 | 3.7 | 290M USD | Not meaningful (loss) | -14.6 % | -42.6 % | -5.9 % | 14.7x | 5.4 % | -12.0 % | ||
| 9 | A174900 | 2.1 | 2.2 | 285M USD | Not meaningful (loss) | -328.3 % | 51.4 % | -40.6 % | 0.2x | -3.1 % | 27.3 % |
